FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

wasinington,	D.C.	20343	

<b>STATEMENT</b>	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Lorianne Masuoka K.				<u>I</u>	2. Issuer Name and Ticker or Trading Symbol INVIVO THERAPEUTICS HOLDINGS CORP. [ NVIV ]							5. Relationship of Reportin (Check all applicable) Director  Officer (give title			on(s) to Issu 10% Ov Other (s	/ner	
	IVO THE	irst) RAPEUTICS HC QUARE, SUITE			3. Date of Earliest Transaction (Month/Day/Year) 03/02/2015						X United (give title Soliter (specify below)  Chief Medical Officer						
(Street)			02139	4	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. I Lin	e) X Form f Form f						
(City)	(S	State)	(Zip)	Davissati	C			iuad [			of ar Da	noficial	ly Oyers and				
1. Title of Security (Instr. 3)  2. Trans. Date			2. Transacti	Execution Date, if any (Month/Day/Year)  Execution Date, if any (Month/Day/Year)  Transaction Code (Instr. 3, 4)		ed (A) or str. 3, 4 and	5. Amou Securitie Beneficie Owned F Reporter Transact	5. Amount of 6. C Securities For Beneficially (D)		Direct Indirect str. 4)	7. Nature of ndirect Beneficial Ownership Instr. 4)						
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
Derivative   Conversion   Date		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	xecution Date, Transac		saction Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	e s dly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)		Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	011(3)	~, 	
Stock Option (Right to Buy)	\$3.02	03/02/2015		A		500,000		(1)	03	3/02/2025	Common Stock	500,000	\$0	500,00	00	D	

## Explanation of Responses:

1. The option is exercisable as to 25% of the shares on the first anniversary of the date of grant, and the remaining shares vest thereafter on a monthly basis in 36 equal monthly installments.

/s/ Elizabeth W. Fraser, Attorney-in-Fact 03/04/2015

\*\* Signature of Reporting Person Dat

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.